Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
28 Fulvestrant Trials Near You
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerThe goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation.
The main question the study aims to answer is:
• To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Lung Disease, QTc Syndrome, Thrombophilia, Others
Must Not Be Taking:CYP3A4 Inhibitors, CYP3A4 Inducers
500 Participants Needed
This trial is testing a combination of drugs to treat advanced breast cancer that has not responded to other treatments. The drugs work by blocking growth signals, breaking down estrogen receptors, and stopping cell division. Tamoxifen is a commonly used drug that blocks estrogen receptors to treat breast cancer, but resistance to it often develops.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Diabetes, Brain Metastases, Cardiovascular, Others
Must Be Taking:LHRH Agonists
701 Participants Needed
This trial is testing if a combination of giredestrant and everolimus works better than other hormone treatments plus everolimus in patients with advanced breast cancer who have already tried other treatments. The drugs work by blocking estrogen receptors and a growth pathway in cancer cells. Everolimus has been shown to improve outcomes in breast cancer patients when combined with hormonal treatments.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Chemotherapy, CNS Metastases, Cardiac Disease, Others
Must Be Taking:LHRH Agonists
320 Participants Needed
Imlunestrant + Abemaciclib for Breast Cancer
Columbus, Ohio
This trial is testing a new drug called imlunestrant, alone and in combination with another drug, abemaciclib, for patients with advanced breast cancer that is ER+ and HER2-. Imlunestrant works by blocking estrogen receptors on cancer cells, while abemaciclib stops the cells from multiplying. The goal is to see if these treatments work better than standard hormone therapy.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Visceral Crisis, Brain Metastasis, Others
Must Be Taking:Aromatase Inhibitors
866 Participants Needed
Fulvestrant + Anastrozole for Breast Cancer
Columbus, Ohio
The study is being conducted to determine whether neoadjuvant endocrine therapy with fulvestrant or the combination of anastrozole and fulvestrant, is better than anastrozole when given before surgery to shrink the cancer and stop it from growing. Anastrozole inhibits tumor growth by reducing the levels of estrogen and has been approved by the Food and Drug Administration (FDA) of the United States for use after surgery for postmenopausal women with estrogen receptor positive breast cancer. It is also considered a standard of care to give anastrozole for a few months before surgery to shrink the tumor. Fulvestrant inhibits tumor cell growth by reducing the levels of estrogen receptor in the tumor cell. It is not approved by the FDA for use in women with early stage breast cancer before or after surgery, but is approved by the FDA for patients with advanced (Stage 4) estrogen receptor positive breast cancer that has spread to other parts of the body.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Sex:Female
Key Eligibility Criteria
Disqualifiers:Premenopausal, Inflammatory Breast Cancer, Others
Must Be Taking:Anastrozole, Fulvestrant
1473 Participants Needed
Fulvestrant vs Anastrozole for Breast Cancer
Columbus, Ohio
The purpose of the study is to compare how treatment with Fulvestrant (FASLODEX) or Anastrozole (ARIMIDEX) effects disease progression for women with locally advanced or metastatic breast cancer who have not had prior hormonal treatment.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Sex:Female
Key Eligibility Criteria
Disqualifiers:Life-threatening Metastasis, Extensive Hepatic, Brain Involvement, Symptomatic Pulmonary, Prior Systemic Therapy, Others
462 Participants Needed
Targeted Therapy for Solid Tumors
Columbus, Ohio
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Solid Tumors, Advanced Stage, Others
2900 Participants Needed
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Distant Metastases, Major Surgery, Others
Must Be Taking:Endocrine Therapy
200 Participants Needed
DNA-Guided Adjuvant Therapy for Breast Cancer
Columbus, Ohio
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Invasive Cancer, HER2 Positive, Others
Must Be Taking:Aromatase Inhibitors, Tamoxifen
70 Participants Needed
Hormone Therapy for Breast Cancer
Columbus, Ohio
This phase II clinical trial studies how well fulvestrant and palbociclib works in treating older patients with breast cancer that responds to hormone treatment (hormone responsive) that cannot be removed by surgery. Estrogen can cause the growth of estrogen-receptor-positive breast cancer cells. Hormone therapy using fulvestrant may fight estrogen-receptor-positive breast cancer by blocking the use of estrogen by the tumor cells. Palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving fulvestrant together with palbociclib may be an effective treatment for hormone responsive breast cancer.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:65+
Sex:Female
Key Eligibility Criteria
Disqualifiers:Aromatase Inhibitors, Metastases, Psychiatric Illness, Others
Must Not Be Taking:CYP3A4 Inducers/inhibitors
14 Participants Needed
STX-478 + Fulvestrant for Advanced Breast Cancer
Columbus, Ohio
This trial is testing a new drug called STX-478 to see if it can help treat advanced solid tumors and breast cancer. The study will look at how safe the drug is, how it behaves in the body, and if it can stop or slow down cancer growth. Some patients will receive just STX-478, while others will get it combined with another drug called fulvestrant, which is often used to treat advanced breast cancer.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Diabetes, Brain Metastases, Others
Must Be Taking:Fulvestrant, CDK4/6 Inhibitors
720 Participants Needed
CFI-402257 + Fulvestrant for Breast Cancer
Columbus, Ohio
This trial tests a new drug, CFI-402257, alone and with Fulvestrant in patients with advanced solid tumors and advanced breast cancer. It aims to determine if the drug is safe and effective by studying its effects on the body and cancer cells. Fulvestrant is an established treatment for hormone receptor-positive advanced breast cancer, often used in combination with other therapies to improve outcomes.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Infections, Cardiovascular, Others
Must Be Taking:CDK4/6 Inhibitors
44 Participants Needed
The purpose of this study to find out whether a very low carbohydrate diet (ketogenic diet), a low carbohydrate diet, or the study drug canagliflozin can prevent high blood sugar and may improve the effectiveness of cancer therapy in people who are receiving standard treatment with alpelisib and fulvestrant for their metastatic PIK3CA-mutant breast cancer.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Type 1 Diabetes, Uncontrolled Type 2 Diabetes, Vegetarian, Others
Must Be Taking:Metformin
15 Participants Needed
BGB-43395 Combinations for Breast Cancer
Columbus, Ohio
This is a dose escalation and dose expansion study to compare how well BGB-43395, a cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with either fulvestrant or letrozole in participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-43395.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Uncontrolled Diabetes, Brain Metastases, Others
Must Be Taking:Endocrine Therapy
79 Participants Needed
OP-1250 for Advanced Breast Cancer
Dayton, Ohio
This trial is testing a new drug called palazestrant to see if it works better than current treatments for adults with advanced breast cancer that has not responded to previous therapies. The drug aims to stop cancer growth by blocking estrogen.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Visceral Disease, CNS Metastases, Cardiac, Others
Must Be Taking:GnRH Agonist
510 Participants Needed
Alpelisib + Fulvestrant for Endometrial Cancer
Kettering, Ohio
This trial tests a combination of two drugs, alpelisib and fulvestrant, in patients with a specific type of endometrial cancer. These patients have a genetic mutation (PIK3CA) and their cancer grows in response to estrogen. Alpelisib targets the mutation, while fulvestrant blocks estrogen, aiming to stop cancer growth. Alpelisib is the first drug of its kind approved for use with fulvestrant based on its effectiveness in treating similar types of cancer.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Sex:Female
Key Eligibility Criteria
Disqualifiers:Diabetes, Cardiac Disease, Active Infection, Others
Must Not Be Taking:Fulvestrant, PIK3CA Inhibitors
51 Participants Needed
Giredestrant vs. Fulvestrant for Advanced Breast Cancer
Cincinnati, Ohio
This trial is testing two drug combinations to treat a specific type of advanced breast cancer that no longer responds to standard hormone treatments. The goal is to see which combination works better by stopping the cancer cells from growing.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Cardiac Disease, Liver Disease, Others
Must Be Taking:LHRH Agonists
1050 Participants Needed
This trial is testing two drug combinations to find out which one is better for treating a specific type of advanced breast cancer that hasn't responded to previous treatments. The drugs work by stopping cancer cells from growing and spreading.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Diabetes, CNS Metastases, Others
Must Be Taking:LHRH Agonists
400 Participants Needed
Giredestrant for Advanced Breast Cancer
Ashland, Kentucky
This trial is testing giredestrant, a new drug, to see if it works better than usual hormone treatments for certain breast cancer patients. It targets patients whose cancer grows with the help of estrogen and who have already tried other treatments. The drug aims to block a protein that helps the cancer grow.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:CNS Metastases, Cardiac Disease, Others
Must Be Taking:LHRH Agonists
303 Participants Needed
This trial compares a new pill (AZD9833) with an existing injection for treating advanced breast cancer in post-menopausal women. It targets women with a specific type of breast cancer that relies on estrogen to grow. Both treatments work by blocking estrogen receptors to slow down or stop cancer growth.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Sex:Female
Key Eligibility Criteria
Disqualifiers:Cardiovascular Issues, CNS Disease, Others
Must Not Be Taking:Hormone Therapy, CYP Inhibitors
240 Participants Needed
Why Other Patients Applied
"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."
WR
Obesity PatientAge: 58
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."
FF
ADHD PatientAge: 31
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
ARV-471 for Breast Cancer
Akron, Ohio
This trial tests a new oral medicine, ARV-471, against an existing injectable treatment, fulvestrant, in people with advanced breast cancer that has spread. Both medicines aim to slow cancer growth by targeting estrogen receptors. ARV-471 is developed as an oral alternative to fulvestrant.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Visceral Spread, Brain Metastases, Others
Must Be Taking:CDK4/6 Inhibitors
624 Participants Needed
Ribociclib Combination Therapy for Breast Cancer
Cleveland, Ohio
This is an open-label, multi-center, roll-over study to evaluate the long term safety of ribociclib in combination with other drugs in participants who are participating in a Novartis sponsored global study, that has fulfilled requirements for its primary objective(s), and who in the opinion of the Investigator, would benefit from continued treatment.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Key Eligibility Criteria
Disqualifiers:Unresolved Toxicities, Others
Must Be Taking:Ribociclib
137 Participants Needed
Regorafenib + Fulvestrant for Ovarian Cancer
Cleveland, Ohio
This trial tests how well Regorafenib combined with hormone therapy works for patients with recurrent low-grade serous ovarian cancer. Regorafenib helps by stopping cancer cells from growing and forming new blood vessels. The treatment continues until the cancer progresses or side effects become too severe.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Sex:Female
Key Eligibility Criteria
Disqualifiers:Hypertension, Cardiac Disease, HIV, Others
Must Not Be Taking:Herbal Remedies
31 Participants Needed
Capivasertib + CDK4/6 Inhibitors + Fulvestrant for Breast Cancer
Fort Wayne, Indiana
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Other Malignancy, Radiotherapy, Major Surgery, Others
Must Be Taking:CDK4/6 Inhibitors, Fulvestrant
895 Participants Needed
Abemaciclib + Fulvestrant for Breast Cancer
Anderson, Indiana
The main purpose of this study is to compare progression-free survival for women with hormone receptor positive (HR+), human epidermal growth factor receptor (HER2) negative advanced breast cancer receiving either abemaciclib + fulvestrant or fulvestrant alone. Participants will be randomized to abemaciclib or placebo in a 2:1 ratio. The study will last about 9 months for each participant.
For the endocrine naïve cohort, all participants will received abemaciclib + fulvestrant.
Prior Safety Data
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Sex:Female
Key Eligibility Criteria
Disqualifiers:CNS Metastasis, Visceral Crisis, Others
Must Be Taking:GnRH Agonists
669 Participants Needed
Fulvestrant + Ipatasertib for Breast Cancer
Windsor, Ontario
The purpose of this study is to find out whether a new drug, Ipatasertib, can slow the growth of advanced breast cancer when added to standard therapy (Fulvestrant).
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:CNS Metastases, Diabetes, Liver Diseases, Others
Must Be Taking:LHRH Agonist
250 Participants Needed
Pembrolizumab + Standard Therapy for Breast Cancer
Detroit, Michigan
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.
The primary study hypotheses are: 1) pembrolizumab is superior to placebo, both in combination with the protocol-specified neoadjuvant anticancer therapy, as assessed by pathological Complete Response (pCR) rate defined by the local pathologist, and 2) pembrolizumab is superior to placebo (both in combination with the protocol-specified neoadjuvant and adjuvant anticancer therapies) as assessed by Event-Free Survival (EFS) as determined by the investigator. The study is considered to have met its primary objective if pembrolizumab is superior to placebo with respect to either pCR (ypT0/Tis ypN0) or EFS.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Pneumonitis, Metastatic Cancer, Autoimmune, Others
Must Not Be Taking:Steroids, Immunosuppressants
1240 Participants Needed
Abemaciclib + Fulvestrant for Breast Cancer
Indianapolis, Indiana
This trial is testing a combination of two drugs, abemaciclib and fulvestrant, for treating a specific type of breast cancer that has not responded to previous treatments. Abemaciclib is taken orally and is approved for treating certain types of breast cancer. The goal is to see if this combination can help stop the cancer from growing. The study may last several years, depending on how well the treatment works for each patient.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Visceral Crisis, CNS Metastasis, Others
Must Be Taking:Endocrine Therapy
368 Participants Needed
Know someone looking for new options?
Spread the word
Learn More About Power
We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.
Bask GillCEO at Power
Frequently Asked Questions
How much do clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.How do clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length is 12 months.How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.Do I need to be insured to participate in a medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.What are the newest clinical trials ?
Most recently, we added Alpelisib + Fulvestrant for Endometrial Cancer, Giredestrant vs. Fulvestrant for Advanced Breast Cancer and BGB-43395 Combinations for Breast Cancer to the Power online platform.Popular Searches
By Condition
By Location
Other People Viewed
By Subject
By Trial
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.